



## PERIOD JANUARY–SEPTEMBER 2007

- Revenue MSEK 3.1 (MSEK 8.1)
- Gross profit MSEK 1.5 (MSEK 4.3)
- Operating result MSEK –19.5 (MSEK –19.6)
- Result before income tax MSEK –19.5 (MSEK –19.7)
- Earnings per share SEK –0.05 (SEK –0.06), diluted
- Equity ratio 76 percent (68 percent)
- Cash and cash equivalents MSEK 4.6 (MSEK 4.1)
- The average number of employees during the period was 19 persons (20 persons)

## THIRD QUARTER, JULY–SEPTEMBER 2007

- Revenue MSEK 1.6 (MSEK 0.6)
- Gross profit MSEK 0.9 (MSEK 0.4)
- Operating result MSEK –4.8 (MSEK –7.1)
- Result before income tax MSEK –4.6 (MSEK –7.3)
- Earnings per share SEK –0.01 (MSEK –0.02), diluted

### INCOME STATEMENT, SUMMARY

(Amounts in SEK thousand)	Jan-Sept		Juli-Sept		Helår
	2007	2006	2007	2006	2006
Revenue	3 107	8 137	1 574	637	10 364
Cost of sales	-1 638	-3 818	-709	-228	-5 093
<b>Gross result</b>	<b>1 469</b>	<b>4 319</b>	<b>865</b>	<b>409</b>	<b>5 271</b>
Other operating expenses/income	-20 954	-23 876	-5 616	-7 541	-31 901
Finance net	31	-168	90	-173	153
<b>NET RESULT FOR THE YEAR</b>	<b>-19 454</b>	<b>-19 725</b>	<b>-4 661</b>	<b>-7 305</b>	<b>-26 477</b>

### Key financial indicators

Result per share, after dilution	-0,05	-0,06	-0,01	-0,02	-0,07
Gross margin	47%	53%	55%	64%	51%
Operating margin	neg	neg	neg	neg	neg
Revenue per employee	164	407	83	32	518

### BALANCE SHEET, SUMMARY

(Amounts in SEK thousand)	30-sep	30-sep
	2007	2006
Non-current assets	33 986	35 155
Inventories	3 546	4 448
Current assets	3 339	3 510
Cash	4 633	4 133
<b>Total assets</b>	<b>45 504</b>	<b>47 246</b>
Equity	34 575	32 115
Liabilities	10 929	15 131
<b>Total equity and liabilities</b>	<b>45 504</b>	<b>47 246</b>

### Key financial indicators

Numbers of shares outstanding* (000's)	355 747	320 779
Numbers of shares after dilution** (000's)	425 402	355 747
Equity ratio %	76%	68%

\* As of the date of reporting

\*\* After conversion/redemption of option programme

## SIGNICANT EVENTS

- After the period under review, Biosensor has acquired a complementary technology via a newly started subsidiary in Germany. This means that Biosensor takes over know-how and patents, as well as gradually taking over development that will lead to the next generation of detection systems. This acquisition is partially financed by the newly completed new issue.
- The new issue, with preferential rights for existing shareholders, was completed after the end of the period under review. The issue was more than 18 percent over-subscribed and the number of shares outstanding will increase by 50,821,016 class A shares and the share capital increases by SEK 5,082,101. The total proceeds of the issue is MSEK 35.6 before issuing costs.
- A private placement was initiated after the end of the period under review aimed at those who had expressed an interest in the rights issue. With full subscription, the number of shares outstanding rises to 9,253,946 class A shares and the share capital increase by SEK 925,394.
- Sales during the period were lower than budget, but higher compared to the equivalent period one year ago. As previously indicated longer testing periods are required in connection with procurement procedures and this has had a negative effect on sales relative to budget.
- Tests of the Company's detection equipment are currently being conducted by potential customers in seven countries, which is more than originally planned.

- A patent that protects a significant portion of the Company's technology for detection of trace substances has been granted in Japan.
- A major German corporation has ordered a BIOSENS® system for detection of explosives. The company is active on a world-wide basis and has chosen Biosensor's system in order to further improve its capacity to protect itself against different terror threats.
- Biosensor has received an initial order for two BIOSENS®-systems from the Indonesian narcotics police. The order constitutes the first part of a total of five systems to be delivered to one of more than fifty districts in Indonesia. The order marks the offensive that local governments have begun to fight narcotics.
- Biosensor has been approved according to ISO-9001.

### GENERAL INFORMATION

**Biosensor Applications®** Biosensor is a Swedish company located in Sundbyberg, a suburb of Stockholm. The Company is listed on AktieTorget. The Company has developed a unique technology for detection of trace substances based on biotechnological sensors. This technology simultaneously detects both explosives and narcotics at a molecular level. The technology is distinguished by its very high probability of detection, with low false alarm rates outside laboratory environments. Biosensor's customers are found among police forces, security companies, border control, the armed forces, the criminal justice system and rehabilitation clinics on a world-wide basis.

For further information, contact: Bengt Hagander, President, +46 8 706 75 00.

Future reports: Year-end report for 2007 in February 2008. The quarterly report, which was prepared in accordance with IFRS, has not been subject to examination by the Company's auditor.